IGF::OT::IGF NExT Mcl-1 NX232-108-172-001 TO#3 Exploratory Tox Study in Dogs Admin Mcl-1 Inhibitor Orally, 8/11/17-12/31/18, Pre-clin Tox & Pharm Study of Drug Dev for Cancer & Other Diseases, HHSN26

Battelle Centers/Pub Hlth Res & Evaluatn, Columbus OH

Investigators

Abstract

The test agent is being considered for development as an anticancer therapeutic. The objective of this task was to characterize the target organ toxicities of an investigative agent that might move forward to clinical testing for anticancer activity. The information obtained from this investigation was used to identify drugs with the potential to treat cancer.